Loading organization details...
Loading organization details...
Source: IRS e-Filed Form 990 (from the IRS e-File system), Tax Year 2024
Total Revenue
▼$664.9K
Program Spending
70%
of total expenses go to program services
Total Contributions
$664.8K
Total Expenses
▼$625.3K
Total Assets
$32.1K
Total Liabilities
▼$26.7K
Net Assets
$5,465
Officer Compensation
→$140.9K
Other Salaries
$100.4K
Investment Income
$95
Fundraising
▼N/A
Source: USAspending.gov · Searched by organization name
VA/DoD Awards
$498.7K
VA/DoD Award Count
1
Funding from the Department of Veterans Affairs and/or Department of Defense.
Total Federal Funding
$11.4M
Awards Found
10
| Awarding Agency | Description | Amount | Fiscal Year | Period |
|---|---|---|---|---|
| Department of Health and Human Services | MECHANISMS OF CHRONIC HEPATITIS B INFECTION AND THERAPEUTIC VACCINES | $3.1M | FY1984 | May 1984 – Jun 2012 |
| Department of Health and Human Services | MULTIEPITOPE CIRCUMSPOROZOITE P.FALCIPARUM MALARIA SUBUNIT VACCINE DISPLAYED ON V | $2.4M | FY2009 | Sep 2009 – Aug 2013 |
| Department of Health and Human Services | EPITOPE-BASED CSP VACCINES OPTIMIZED TO ACHIEVE LONG-TERM STERILE IMMUNITY - ABSTRACT GIVEN THE VERY HIGH BURDEN MALARIA IMPOSES ON MANY DEVELOPING COUNTRIES AND THE CONTINUED NEED FOR AN EFFECTIVE VACCINE, THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP A PLASMODIUM FALCIPARUM (PF) VACCINE BY TAKING ADVANTAGE OF THE KNOWLEDGE GAINED IN THE LAST FEW YEARS ISOLATING AND CHARACTERIZING PROTECTIVE HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR MAJOR COAT PROTEIN OF THE PARASITE, CIRCUMSPOROZOITE (CS) PROTEIN. THE MALARIA VACCINE CANDIDATES CURRENTLY MOST ADVANCED IN THE CLINIC, RTS,S AND R21, TARGET ONLY THE MAJOR NANP REPEAT OF THE PFCS PROTEIN PLUS T CELL EPITOPES IN THE C-TERMINAL DOMAIN. CURRENT LIMITATIONS OF THE RTS,S VACCINE HAVE BEEN THE 30-50% EFFICACY AND TRANSIENT PROTECTION. A FURTHER POTENTIAL COMPLICATION IS PRE-EXISTING IMMUNITY/TOLERANCE TO THE HBSAG CARRIER, WHICH IS DERIVED FROM A HUMAN PATHOGEN. TO CIRCUMVENT THESE PROBLEMS WE HAVE DEVELOPED A NON-HUMAN PATHOGEN-DERIVED CARRIER PLATFORM, SPECIFICALLY THE CORE PROTEIN FROM THE WOODCHUCK HEPADNAVIRUS (WHCAG). MODIFIED WHCAG VLPS ARE USED AS THE VACCINE PLATFORM FOR SEVERAL REASONS: WHC-CS HYBRID VLPS ELICIT EXTREMELY HIGH LEVELS OF ANTI-CS PROTECTIVE ANTIBODIES; NEW PROTECTIVE EPITOPES CAN BE ADDED SIMPLY; AND SINCE WHC-CS HYBRID VLPS CAN BE MADE IN BACTERIA, THE VACCINE WILL HAVE A LOW COST-OF-GOODS. IN PRELIMINARY STUDIES WE DEVELOPED A WHC-CS HYBRID VLP THAT CONTAINS TWO NEUTRALIZING PF-CS REPEAT B CELL EPITOPES AND THREE “UNIVERSAL” MALARIA-SPECIFIC T CELL DOMAINS. THIS WHC-CS HYBRID VLP (DESIGNATED VLP-162) IS VERY IMMUNOGENIC IN MICE AND RABBITS AND ELICITS NEUTRALIZING ANTI-CS REPEAT ANTIBODIES THAT PREVENT P. BERGHEI/PF HYBRID SPOROZOITE LIVER INFECTION IN VIVO AND PRODUCES STERILE IMMUNITY TO BLOOD STAGE INFECTION IN 90-100% OF MICE. OUR APPROACH IS TO EXPAND THE SCOPE AND PROTECTIVE EFFICACY OF VLP-162 BY ADDING B CELL EPITOPES DEFINED BY THE PROTECTIVE HUMAN MABS CIS43, 313/317, L9 AND 5D5, PLUS EXPAND THE CS-SPECIFIC T CELL EPITOPES DELIVERED BY THE VLP. THE STRATEGY FOR DEVELOPING AN OPTIMAL NEXT-GENERATION MALARIA VACCINE IS DIVIDED INTO 3 AIMS: AIM 1) BUILD ON VLP-162 BY INCORPORATION OF THE NEWLY DEFINED CS-DERIVED PROTECTIVE B CELL EPITOPES AND BROADENING THE NUMBER OF CS-SPECIFIC T CELL EPITOPES; AIM 2) OPTIMIZE IMMUNOGENICITY BY ASSESSING ADJUVANT FORMULATIONS IN MULTIPLE MOUSE STRAINS; AND AIM 3) CONDUCT IN VIVO PROTECTIVE EFFICACY TESTS IN PF MOUSE CHALLENGE MODELS USING PBPF HYBRID SPOROZOITES THAT CONTAIN THE ENTIRE PF CS OR ENGINEERED PF CS PROTEINS THAT ALLOW US TO MEASURE THE CONTRIBUTION OF EACH EPITOPE TO PROTECTIVE EFFICACY. COMBINATION OF THESE TWO TECHNOLOGIES, THE WHCAG PLATFORM AND THE PBPF HYBRID SPOROZOITE CHALLENGE MODELS, WILL ALLOW IN VIVO PROTECTIVE EFFICACY TO BE DETERMINED IN INFECTIOUS MODEL SYSTEMS. | $2.1M | FY2023 | Aug 2023 – Jul 2026 |
| Department of Health and Human Services | SALMONELLA GENES ASSOCIATED WITH COLONIZATION OF SPECIFIC HOSTS | $927.8K | FY2009 | Jul 2009 – Apr 2011 |
| Department of Health and Human Services | A MOLECULAR METHOD TO DETERMINE ISOFORM FREQUENCIES IN RNA-SEQ | $770K | FY2015 | Sep 2015 – Feb 2019 |
| Department of Health and Human Services | DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM | $531.8K | FY2000 | Sep 2000 – Jun 2009 |
| VA/DoDDepartment of Defense | ENGINEERING IMPROVEMENTS IN A BACTERIAL THERAPEUTIC DELIVERY SYSTEM FOR BREAST CANCER | $498.7K | FY2008 | Sep 2008 – Sep 2011 |
| Department of Health and Human Services | TRACKING CANCER STEM CELL EVOLUTION | $475.2K | FY2008 | Aug 2008 – Jul 2010 |
| Department of Health and Human Services | ARRAYS AND TARGETS FOR NASCENT TRANSCRIPTS | $366K | FY1992 | Mar 1992 – Jun 2010 |
| Department of Health and Human Services | VALIDATION OF A NEW TARGET FOR PROSTATE CANCER THERAPY | $289.7K | FY2004 | Apr 2004 – Aug 2010 |
Department of Health and Human Services
$3.1M
MECHANISMS OF CHRONIC HEPATITIS B INFECTION AND THERAPEUTIC VACCINES
Department of Health and Human Services
$2.4M
MULTIEPITOPE CIRCUMSPOROZOITE P.FALCIPARUM MALARIA SUBUNIT VACCINE DISPLAYED ON V
Department of Health and Human Services
$2.1M
EPITOPE-BASED CSP VACCINES OPTIMIZED TO ACHIEVE LONG-TERM STERILE IMMUNITY - ABSTRACT GIVEN THE VERY HIGH BURDEN MALARIA IMPOSES ON MANY DEVELOPING COUNTRIES AND THE CONTINUED NEED FOR AN EFFECTIVE VACCINE, THE OBJECTIVE OF THIS PROPOSAL IS TO DEVELOP A PLASMODIUM FALCIPARUM (PF) VACCINE BY TAKING ADVANTAGE OF THE KNOWLEDGE GAINED IN THE LAST FEW YEARS ISOLATING AND CHARACTERIZING PROTECTIVE HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR MAJOR COAT PROTEIN OF THE PARASITE, CIRCUMSPOROZOITE (CS) PROTEIN. THE MALARIA VACCINE CANDIDATES CURRENTLY MOST ADVANCED IN THE CLINIC, RTS,S AND R21, TARGET ONLY THE MAJOR NANP REPEAT OF THE PFCS PROTEIN PLUS T CELL EPITOPES IN THE C-TERMINAL DOMAIN. CURRENT LIMITATIONS OF THE RTS,S VACCINE HAVE BEEN THE 30-50% EFFICACY AND TRANSIENT PROTECTION. A FURTHER POTENTIAL COMPLICATION IS PRE-EXISTING IMMUNITY/TOLERANCE TO THE HBSAG CARRIER, WHICH IS DERIVED FROM A HUMAN PATHOGEN. TO CIRCUMVENT THESE PROBLEMS WE HAVE DEVELOPED A NON-HUMAN PATHOGEN-DERIVED CARRIER PLATFORM, SPECIFICALLY THE CORE PROTEIN FROM THE WOODCHUCK HEPADNAVIRUS (WHCAG). MODIFIED WHCAG VLPS ARE USED AS THE VACCINE PLATFORM FOR SEVERAL REASONS: WHC-CS HYBRID VLPS ELICIT EXTREMELY HIGH LEVELS OF ANTI-CS PROTECTIVE ANTIBODIES; NEW PROTECTIVE EPITOPES CAN BE ADDED SIMPLY; AND SINCE WHC-CS HYBRID VLPS CAN BE MADE IN BACTERIA, THE VACCINE WILL HAVE A LOW COST-OF-GOODS. IN PRELIMINARY STUDIES WE DEVELOPED A WHC-CS HYBRID VLP THAT CONTAINS TWO NEUTRALIZING PF-CS REPEAT B CELL EPITOPES AND THREE “UNIVERSAL” MALARIA-SPECIFIC T CELL DOMAINS. THIS WHC-CS HYBRID VLP (DESIGNATED VLP-162) IS VERY IMMUNOGENIC IN MICE AND RABBITS AND ELICITS NEUTRALIZING ANTI-CS REPEAT ANTIBODIES THAT PREVENT P. BERGHEI/PF HYBRID SPOROZOITE LIVER INFECTION IN VIVO AND PRODUCES STERILE IMMUNITY TO BLOOD STAGE INFECTION IN 90-100% OF MICE. OUR APPROACH IS TO EXPAND THE SCOPE AND PROTECTIVE EFFICACY OF VLP-162 BY ADDING B CELL EPITOPES DEFINED BY THE PROTECTIVE HUMAN MABS CIS43, 313/317, L9 AND 5D5, PLUS EXPAND THE CS-SPECIFIC T CELL EPITOPES DELIVERED BY THE VLP. THE STRATEGY FOR DEVELOPING AN OPTIMAL NEXT-GENERATION MALARIA VACCINE IS DIVIDED INTO 3 AIMS: AIM 1) BUILD ON VLP-162 BY INCORPORATION OF THE NEWLY DEFINED CS-DERIVED PROTECTIVE B CELL EPITOPES AND BROADENING THE NUMBER OF CS-SPECIFIC T CELL EPITOPES; AIM 2) OPTIMIZE IMMUNOGENICITY BY ASSESSING ADJUVANT FORMULATIONS IN MULTIPLE MOUSE STRAINS; AND AIM 3) CONDUCT IN VIVO PROTECTIVE EFFICACY TESTS IN PF MOUSE CHALLENGE MODELS USING PBPF HYBRID SPOROZOITES THAT CONTAIN THE ENTIRE PF CS OR ENGINEERED PF CS PROTEINS THAT ALLOW US TO MEASURE THE CONTRIBUTION OF EACH EPITOPE TO PROTECTIVE EFFICACY. COMBINATION OF THESE TWO TECHNOLOGIES, THE WHCAG PLATFORM AND THE PBPF HYBRID SPOROZOITE CHALLENGE MODELS, WILL ALLOW IN VIVO PROTECTIVE EFFICACY TO BE DETERMINED IN INFECTIOUS MODEL SYSTEMS.
Department of Health and Human Services
$927.8K
SALMONELLA GENES ASSOCIATED WITH COLONIZATION OF SPECIFIC HOSTS
Department of Health and Human Services
$770K
A MOLECULAR METHOD TO DETERMINE ISOFORM FREQUENCIES IN RNA-SEQ
Department of Health and Human Services
$531.8K
DEVELOPMENT OF THE HBCAG AS A VACCINE CARRIER PLATFORM
Department of Defense
$498.7K
ENGINEERING IMPROVEMENTS IN A BACTERIAL THERAPEUTIC DELIVERY SYSTEM FOR BREAST CANCER
Department of Health and Human Services
$475.2K
TRACKING CANCER STEM CELL EVOLUTION
Department of Health and Human Services
$366K
ARRAYS AND TARGETS FOR NASCENT TRANSCRIPTS
Department of Health and Human Services
$289.7K
VALIDATION OF A NEW TARGET FOR PROSTATE CANCER THERAPY
Source: Federal Audit Clearinghouse (fac.gov)
No federal single audit records found for this organization.
Single audits are required for entities expending $750,000+ in federal awards annually.
Tax Year 2025 · Source: IRS e-Filed Form 990
Individuals serving as officers, directors, or trustees of the organization.
| Name | Title | Hrs/Wk | Compensation | Related Orgs | Other |
|---|
Source: IRS Publication 78, Auto-Revocation List & e-Postcard Data
Tax-deductible contributions: Yes
Deductibility code: PC
990-N (e-Postcard) Filing History
This organization files simplified Form 990-N (annual gross receipts ≤ $50,000).
Sources: IRS e-Filed Form 990 (XML) & ProPublica Nonprofit Explorer
Scroll →
| Year | Revenue | Contributions | Expenses | Assets | Net Assets |
|---|---|---|---|---|---|
| 2024IRS e-File | $664.9K | $664.8K | $625.3K | $32.1K | $5,465 |
| 2021 | $2,015 | — | $16.6K | $21.6K | — |
| 2020 | $100.1K | — | $136K | $40K | — |
| 2019 | $450.8K | $450.6K | $398.8K |
Sources: ProPublica Nonprofit Explorer & IRS e-File Index
| Tax Year | Form Type | Source | Documents |
|---|---|---|---|
| 2025 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2024 | 990 | IRS e-File | PDF not yet published by IRSView Filing → |
| 2021 | 990-EZ | Data |
Financial data: IRS e-Filed Form 990 (Tax Year 2024)
Leadership & compensation: IRS e-Filed Form 990, Part VII (Tax Year 2025)
Federal grants: USAspending.gov (live)
Organization info: IRS Business Master File
Tax-deductibility: IRS Publication 78
| Total |
|---|
| David Whitacre | Sec/treas | 20 | $74.4K | $0 | $3,850 | $78.3K |
| David R Milich | President | 20 | $56K | $0 | $2,801 | $58.8K |
| Joyce Jones | CEO | 5 | $12K | $0 | $0 | $12K |
David Whitacre
Sec/treas
$78.3K
Hrs/Wk
20
Compensation
$74.4K
Related Orgs
$0
Other
$3,850
David R Milich
President
$58.8K
Hrs/Wk
20
Compensation
$56K
Related Orgs
$0
Other
$2,801
Joyce Jones
CEO
$12K
Hrs/Wk
5
Compensation
$12K
Related Orgs
$0
Other
$0
| $103.8K |
| $71.3K |
| 2018 | $767.4K | $767.2K | $813.4K | $274.4K | $19.3K |
| 2017 | $1M | $1M | $1.1M | $331.1K | $65.3K |
| 2016 | $903.1K | $902.9K | $921.2K | $375.3K | $84.5K |
| 2015 | $874.4K | $874.2K | $855.8K | $354.3K | $102.6K |
| 2014 | $993.6K | $993.3K | $1M | $300.2K | $84.1K |
| 2013 | $1.5M | $1.5M | $1.4M | $387.5K | $101.6K |
| 2012 | $2.4M | $2.3M | $2.3M | $399.2K | $31.1K |
| 2011 | $3.2M | $3.1M | $3.1M | $659.7K | -$25K |
| 2020 | 990-EZ | Data |
| 2019 | 990 | Data |
| 2018 | 990 | Data |
| 2017 | 990 | Data |
| 2016 | 990 | Data |
| 2015 | 990 | Data |
| 2014 | 990 | Data |
| 2013 | 990 | Data |
| 2012 | 990 | Data |
| 2011 | 990 | Data |
| 2010 | 990 | — |
| 2009 | 990 | — |
| 2008 | 990 | — |
| 2007 | 990 | — |
| 2005 | 990 | — |
| 2004 | 990 | — |
| 2003 | 990 | — |
| 2002 | 990 | — |
| 2001 | 990 | — |